|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STARD3 |
Gene summary for STARD3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STARD3 | Gene ID | 10948 |
| Gene name | StAR related lipid transfer domain containing 3 | |
| Gene Alias | CAB1 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | Q14849 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10948 | STARD3 | GSM4909291 | Human | Breast | IDC | 3.20e-28 | 7.82e-01 | 0.1753 |
| 10948 | STARD3 | GSM4909292 | Human | Breast | IDC | 1.35e-13 | 9.25e-01 | 0.1236 |
| 10948 | STARD3 | GSM4909293 | Human | Breast | IDC | 8.68e-35 | 6.07e-01 | 0.1581 |
| 10948 | STARD3 | GSM4909294 | Human | Breast | IDC | 1.66e-02 | 2.35e-01 | 0.2022 |
| 10948 | STARD3 | GSM4909319 | Human | Breast | IDC | 9.90e-04 | -3.32e-02 | 0.1563 |
| 10948 | STARD3 | M2 | Human | Breast | IDC | 4.76e-18 | 1.00e+00 | 0.21 |
| 10948 | STARD3 | NCCBC14 | Human | Breast | DCIS | 2.15e-03 | 2.99e-01 | 0.2021 |
| 10948 | STARD3 | NCCBC5 | Human | Breast | DCIS | 1.72e-07 | 4.09e-01 | 0.2046 |
| 10948 | STARD3 | P2 | Human | Breast | IDC | 5.58e-07 | 4.57e-01 | 0.21 |
| 10948 | STARD3 | DCIS2 | Human | Breast | DCIS | 3.71e-13 | 2.94e-02 | 0.0085 |
| 10948 | STARD3 | LZE4T | Human | Esophagus | ESCC | 9.73e-12 | 2.22e-01 | 0.0811 |
| 10948 | STARD3 | LZE5T | Human | Esophagus | ESCC | 2.93e-02 | 2.12e-01 | 0.0514 |
| 10948 | STARD3 | LZE7T | Human | Esophagus | ESCC | 3.56e-07 | 6.05e-01 | 0.0667 |
| 10948 | STARD3 | LZE8T | Human | Esophagus | ESCC | 3.20e-04 | 2.29e-01 | 0.067 |
| 10948 | STARD3 | LZE20T | Human | Esophagus | ESCC | 4.47e-02 | 1.19e-01 | 0.0662 |
| 10948 | STARD3 | LZE22T | Human | Esophagus | ESCC | 2.36e-05 | 4.23e-01 | 0.068 |
| 10948 | STARD3 | LZE24T | Human | Esophagus | ESCC | 2.92e-24 | 7.11e-01 | 0.0596 |
| 10948 | STARD3 | LZE6T | Human | Esophagus | ESCC | 1.13e-04 | 4.10e-01 | 0.0845 |
| 10948 | STARD3 | P1T-E | Human | Esophagus | ESCC | 2.96e-09 | 4.73e-01 | 0.0875 |
| 10948 | STARD3 | P2T-E | Human | Esophagus | ESCC | 3.19e-29 | 4.53e-01 | 0.1177 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000820311 | Oral cavity | LP | cholesterol metabolic process | 47/4623 | 137/18723 | 7.20e-03 | 4.04e-02 | 47 |
| GO:001612511 | Oral cavity | LP | sterol metabolic process | 51/4623 | 152/18723 | 8.57e-03 | 4.63e-02 | 51 |
| GO:005165623 | Oral cavity | EOLP | establishment of organelle localization | 73/2218 | 390/18723 | 4.59e-05 | 6.11e-04 | 73 |
| GO:005165022 | Oral cavity | EOLP | establishment of vesicle localization | 35/2218 | 161/18723 | 2.54e-04 | 2.47e-03 | 35 |
| GO:005164822 | Oral cavity | EOLP | vesicle localization | 37/2218 | 177/18723 | 3.88e-04 | 3.48e-03 | 37 |
| GO:00990221 | Oral cavity | EOLP | vesicle tethering | 6/2218 | 11/18723 | 7.46e-04 | 6.03e-03 | 6 |
| GO:000690321 | Oral cavity | EOLP | vesicle targeting | 13/2218 | 45/18723 | 1.64e-03 | 1.09e-02 | 13 |
| GO:00516569 | Prostate | BPH | establishment of organelle localization | 107/3107 | 390/18723 | 3.67e-08 | 1.03e-06 | 107 |
| GO:00516508 | Prostate | BPH | establishment of vesicle localization | 49/3107 | 161/18723 | 9.12e-06 | 1.28e-04 | 49 |
| GO:00516488 | Prostate | BPH | vesicle localization | 51/3107 | 177/18723 | 3.20e-05 | 3.61e-04 | 51 |
| GO:00069036 | Prostate | BPH | vesicle targeting | 16/3107 | 45/18723 | 1.62e-03 | 9.39e-03 | 16 |
| GO:005165614 | Prostate | Tumor | establishment of organelle localization | 109/3246 | 390/18723 | 9.97e-08 | 2.67e-06 | 109 |
| GO:005165014 | Prostate | Tumor | establishment of vesicle localization | 49/3246 | 161/18723 | 3.02e-05 | 3.62e-04 | 49 |
| GO:005164813 | Prostate | Tumor | vesicle localization | 51/3246 | 177/18723 | 1.03e-04 | 9.96e-04 | 51 |
| GO:000690313 | Prostate | Tumor | vesicle targeting | 16/3246 | 45/18723 | 2.59e-03 | 1.43e-02 | 16 |
| GO:005165624 | Skin | cSCC | establishment of organelle localization | 178/4864 | 390/18723 | 2.18e-17 | 2.32e-15 | 178 |
| GO:000683927 | Skin | cSCC | mitochondrial transport | 124/4864 | 254/18723 | 3.54e-15 | 2.81e-13 | 124 |
| GO:00069039 | Skin | cSCC | vesicle targeting | 28/4864 | 45/18723 | 3.26e-07 | 6.57e-06 | 28 |
| GO:005165018 | Skin | cSCC | establishment of vesicle localization | 70/4864 | 161/18723 | 1.02e-06 | 1.82e-05 | 70 |
| GO:005164816 | Skin | cSCC | vesicle localization | 73/4864 | 177/18723 | 6.36e-06 | 8.92e-05 | 73 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STARD3 | SNV | Missense_Mutation | novel | c.1307N>G | p.Gln436Arg | p.Q436R | Q14849 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STARD3 | SNV | Missense_Mutation | c.140C>T | p.Ser47Phe | p.S47F | Q14849 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| STARD3 | insertion | Frame_Shift_Ins | novel | c.1308_1309insGGGCCTCCCCTTTGTCAGCCACCTTT | p.Arg437GlyfsTer67 | p.R437Gfs*67 | Q14849 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
| STARD3 | insertion | In_Frame_Ins | novel | c.906_907insGTA | p.Leu302_Gln303insVal | p.L302_Q303insV | Q14849 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| STARD3 | insertion | Nonsense_Mutation | novel | c.908_909insCCATTGAAGTTCCCTTTCACGGCAAGACGTTTATCCTGAA | p.Gln303HisfsTer3 | p.Q303Hfs*3 | Q14849 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| STARD3 | deletion | Frame_Shift_Del | novel | c.12delN | p.Arg6GlyfsTer3 | p.R6Gfs*3 | Q14849 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| STARD3 | deletion | Frame_Shift_Del | novel | c.583delN | p.Leu196CysfsTer90 | p.L196Cfs*90 | Q14849 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| STARD3 | SNV | Missense_Mutation | rs143167128 | c.1168N>A | p.Val390Met | p.V390M | Q14849 | protein_coding | tolerated(0.31) | probably_damaging(0.933) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STARD3 | SNV | Missense_Mutation | c.658N>A | p.Glu220Lys | p.E220K | Q14849 | protein_coding | deleterious(0.03) | benign(0.092) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STARD3 | SNV | Missense_Mutation | rs749828666 | c.1271N>T | p.Ala424Val | p.A424V | Q14849 | protein_coding | deleterious(0.01) | benign(0.339) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |